moxifloxacin has been researched along with 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide) | Trials (1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide) | Recent Studies (post-2010) (1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 5 | 0 | 3 |
| Protein | Taxonomy | moxifloxacin (IC50) | 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 0.37 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 0.37 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 0.37 | |
| Procathepsin L | Homo sapiens (human) | 0.37 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 0.37 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 0.37 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 0.2617 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.2617 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 0.37 | |
| Genome polyprotein | Human rhinovirus sp. | 0.004 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and 1-(2-Naphthylmethyl)-2,3-dioxo-indoline-5-carboxamide
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |